Profits up at growing pharmaceutical group

Clinigen chief executive Shaun Clifton

Pharmaceutical group Clinigen has increased profitability by 15%, aided by the strength of its global footprint and diversified portfolio.

Revenues in the six months to December were up 28% to £167.8m at the Burton-based business. This led to its adjusted EBITDA – a measure of operational profitability – increasing to £34.4m.

Clinigen highlighted the strong performance of its commercial medicines division and growth in Africa and Asia Pacific as key factors in its progress.

Shaun Chilton, Clinigen’s chief executive, said: “We have made strong progress against our strategic priorities. We have and will continue to drive organic growth and search for selective acquisitions to complement our existing offering and capabilities.”

Clinigen bought North East business Quantum Pharma for £150m last September and followed it up a month later with the acquisition of Japan’s largest supplier of unlicensed medicine, International Medical Management Corporation, for an undisclosed sum.

He added: “The acquisitions of Quantum and IMMC extend our unlicensed medicines capability and accelerates our unlicensed to licensed global strategy. Both acquisitions are performing well with integration going to plan.

“We are well positioned to deliver another good year of progress.”

Click here to sign up to receive our new South West business news...
Close